GAMMA Investing LLC Has $524,000 Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

GAMMA Investing LLC grew its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 8,947.4% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 17,552 shares of the specialty pharmaceutical company’s stock after purchasing an additional 17,358 shares during the quarter. GAMMA Investing LLC’s holdings in Collegium Pharmaceutical were worth $524,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Collegium Pharmaceutical during the 4th quarter valued at about $3,489,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Collegium Pharmaceutical by 11.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 66,389 shares of the specialty pharmaceutical company’s stock worth $1,902,000 after acquiring an additional 7,063 shares in the last quarter. Velan Capital Investment Management LP bought a new stake in Collegium Pharmaceutical during the 4th quarter worth approximately $822,000. Vident Advisory LLC increased its holdings in Collegium Pharmaceutical by 27.8% during the 4th quarter. Vident Advisory LLC now owns 16,898 shares of the specialty pharmaceutical company’s stock valued at $484,000 after purchasing an additional 3,672 shares in the last quarter. Finally, Virtus Fund Advisers LLC raised its position in Collegium Pharmaceutical by 30.5% in the 4th quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock valued at $69,000 after purchasing an additional 565 shares during the last quarter.

Analysts Set New Price Targets

A number of equities analysts have commented on COLL shares. Wall Street Zen lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 19th. Piper Sandler reissued a “neutral” rating and issued a $37.00 price objective (up previously from $36.00) on shares of Collegium Pharmaceutical in a research note on Friday, May 9th. Needham & Company LLC reissued a “buy” rating and issued a $46.00 price objective on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. Finally, HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus price target of $43.75.

Collegium Pharmaceutical Trading Up 0.5%

COLL stock opened at $29.60 on Thursday. The company has a market cap of $951.05 million, a P/E ratio of 24.26 and a beta of 0.63. Collegium Pharmaceutical, Inc. has a twelve month low of $23.23 and a twelve month high of $42.29. The company has a quick ratio of 1.01, a current ratio of 1.08 and a debt-to-equity ratio of 3.30. The business has a fifty day moving average of $28.40 and a 200-day moving average of $29.55.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share for the quarter, missing analysts’ consensus estimates of $1.50 by ($0.01). The firm had revenue of $177.76 million for the quarter, compared to the consensus estimate of $174.96 million. Collegium Pharmaceutical had a return on equity of 99.08% and a net margin of 6.61%. The company’s revenue was up 22.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.45 EPS. As a group, equities research analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Insider Transactions at Collegium Pharmaceutical

In related news, Director John Gordon Freund sold 6,601 shares of the company’s stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $30.62, for a total value of $202,122.62. Following the completion of the sale, the director now owns 70,658 shares in the company, valued at approximately $2,163,547.96. This represents a 8.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 2.51% of the stock is currently owned by corporate insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.